FindTrial
Sign In

Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)

Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian During Controlled Ovarian Stimulation(COH) for In Vitro Fertilisation(IVF)

Status
Withdrawn
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01109888
Enrollment
0
Registered
2010-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2016-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)

Brief summary

Coasting is one of the means to reduce the risk of OHSS for patients at risk for severe OHSS. During coasting gonadotrophin administration is withheld until serum E2 levels drop to a range considered safe. Prolonged coasting reduces the chance for implantation and pregnancy. The aim of the study is to explore whether an increased dose of GnRH Antagonist will shorten the coasting period without an adverse effect on cycle outcome.

Detailed description

30 patients undergoing IVF using a GnRH antagonist protocol that present with a high response to gonadotrophin stimulation, will be randomized into one of two groups: group A - withdrawal of gonadotrophin support and continue a daily dose of 0.25 mg of the GnRH antagonist. group B - withdrawal of gonadotrophin support and continue a double daily dose of 0.5 mg of the GnRH antagonist. The main outcome measures will be the duration of coasting (days)and the rate of serum E2 drop (%).

Interventions

DRUGCetrotide

Sponsors

Wolfson Medical Center
Lead SponsorOTHER_GOV

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years

Inclusion criteria

30 women undergoing IVF cycle with GnRH Antagonist protocol under 35 years old. E2 higher than 3000 pg/ml. -

Exclusion criteria

3 or more failed fresh IVF cycles. \-

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026